- Home
- KURA vs PGC Comparison
KURA vs PGC Comparison
Compare KURA & PGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KURA | PGC |
|---|---|---|
| Founded | 2014 | 1921 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.6M | 836.7M |
| IPO Year | 2015 | 1997 |
Fundamental Metrics
Financial Performance| Metric | KURA | PGC |
|---|---|---|
| Price | $10.40 | $47.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 2 |
| Target Price | $25.56 | ★ $40.50 |
| AVG Volume (30 Days) | ★ 1.4M | 203.5K |
| Earning Date | 05-12-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 0.48% |
| EPS Growth | N/A | ★ 13.51 |
| EPS | N/A | ★ 0.80 |
| Revenue | $67,482,000.00 | ★ $282,995,000.00 |
| Revenue This Year | $28.28 | $32.39 |
| Revenue Next Year | $106.37 | $12.64 |
| P/E Ratio | ★ N/A | $58.80 |
| Revenue Growth | ★ 25.24 | 24.05 |
| 52 Week Low | $5.45 | $24.45 |
| 52 Week High | $12.49 | $49.14 |
Technical Indicators
Market Signals| Indicator | KURA | PGC |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 56.50 |
| Support Level | $8.53 | $44.12 |
| Resistance Level | $10.97 | $47.18 |
| Average True Range (ATR) | 0.47 | 1.39 |
| MACD | -0.17 | -0.12 |
| Stochastic Oscillator | 10.29 | 84.79 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About PGC Peapack-Gladstone Financial Corporation
Peapack Gladstone Financial Corp is a bank holding company. Through its subsidiaries, the company offers various wealth management, investment banking, and commercial and personal banking solutions to its clients. The company has two reportable segments: Banking, which generates the maximum revenue, and Wealth Management. The Banking segment includes commercial, commercial real estate, multifamily, residential, and consumer lending activities; treasury management services; escrow management; deposit generation; operation of ATMs; telephone and internet banking services; credit card services, etc. The Wealth Management segment offers investment management services for individuals and institutions; personal trust services; and other financial planning and advisory services.